Information Provided By: 
Fly News Breaks for July 14, 2015
CEMP
Jul 14, 2015 | 08:41 EDT
After meeting with Cempra's management, Roth Capital says that the company could secure "a big win" if a study of its Solitaire Oral treatment shows a statistically-significant benefit. The firm notes that results form the study are due out in Q4. It adds that two other treatments being developed by the company, olithromycin and Taksta, provide it with "compelling opportunities" that are not reflected in the stock. The firm keeps a $42 price target and Buy rating on the shares.
News For CEMP From the Last 2 Days
There are no results for your query CEMP
